|1.||Young, Marian F: 16 articles (12/2012 - 02/2002)|
|2.||Schaefer, Liliana: 13 articles (08/2014 - 07/2003)|
|3.||Iozzo, Renato V: 11 articles (05/2015 - 08/2004)|
|4.||Fischer, Jens W: 10 articles (10/2014 - 09/2002)|
|5.||Wight, Thomas N: 8 articles (08/2015 - 01/2002)|
|6.||Tannock, Lisa R: 7 articles (02/2015 - 01/2002)|
|7.||O'Brien, Kevin D: 6 articles (12/2008 - 03/2002)|
|8.||Lechner, Beatrice E: 5 articles (05/2015 - 09/2006)|
|9.||Thompson, Joel C: 5 articles (02/2015 - 03/2008)|
|10.||Wilson, Patricia G: 5 articles (02/2015 - 03/2008)|
07/01/2014 - "The goal of this study was to determine if over-expression of biglycan in hyperlipidemic mice would increase atherosclerosis development. "
08/01/2013 - "Thus, this study demonstrates that neutralization of TGFβ attenuated angII stimulation of biglycan accumulation and atherogenesis in mice, suggesting that TGFβ-mediated biglycan induction is one of the mechanisms underlying angII-promoted atherosclerosis. "
02/01/2015 - "We propose that SAA increases atherosclerosis development via induction of TGF-β, increased vascular biglycan content, and increased LDL retention. "
12/01/2014 - "Biglycan: unpuzzling the causal links between tobacco-smoking and atherosclerosis?"
12/01/2014 - "Biglycan expression in current cigarette smokers: a possible link between active smoking and atherogenesis."
03/01/2008 - "In vivo strain analysis showed that biglycan-null scars were stiffer than the wild-type. "
03/01/2008 - "We hypothesized that biglycan contributes to post-myocardial infarction (MI) scar development and that the absence of biglycan would result in altered scar structure and mechanics. "
03/11/2008 - "Biglycan is required for stable collagen matrix formation of infarct scars and for preservation of cardiac hemodynamic function."
03/01/2008 - "Null-expression of biglycan may alter collagen fibril ultrastructure, and thereby influence scar mechanics and remodeling."
03/01/2008 - "Electron microscopy revealed that collagen fibrils had a smaller average diameter and a narrower range in the biglycan-null scar, as well as appearing more densely packed. "
01/01/1998 - "Biglycan was limited to the most loose and proliferative neointima and stained less than in primary plaques. "
10/01/2000 - "These results indicate that biglycan and decorin kinetics during neointima formation after arterial injury are distinct, despite their similar construction; biglycan synthesis correlates with embryonic SMCs."
02/01/2000 - "Biglycan, but not decorin, accumulated in the neointima of arteriosclerotic blood vessels. "
01/01/2005 - "On the other hand, the neointima near the graft material is enriched in collagen and biglycan. "
10/01/2000 - "Differential expression of proteoglycans biglycan and decorin during neointima formation after stent implantation in normal and atherosclerotic rabbit aortas."
|4.||Chronic Obstructive Pulmonary Disease (COPD)
10/15/2013 - "Our findings suggest that the effects of steroids on the airway compartment may be beneficial for patients with severe COPD, i.e., restoration of decorin loss around the airways, whereas the effects of steroids on the parenchyma may be detrimental, since the tissue repair response, i.e., biglycan and procollagen production, is inhibited. "
01/01/2014 - "Biopsies of segmental bronchi spurs were performed in COPD patients and control smoker subjects and immunostained for collagen type I, versican, decorin, biglycan, and alpha-smooth muscle actin. "
01/01/2013 - "Conversely, iloprost significantly altered biglycan and decorin synthesis in control fibroblasts, but iloprost displayed no effect on these proteoglycans in COPD fibroblasts. "
12/01/2012 - "We determined the fractional areas of elastic fibres, type-I, -III and -IV collagen, versican, decorin, biglycan, lumican, fibronectin and tenascin in different compartments of the large and small airways and lung parenchyma in 26 COPD patients, 26 smokers without COPD and 16 nonsmoking control subjects. "
12/01/2010 - "Overexpression of soluble biglycan in MRL/lpr mice raised plasma and renal levels of CXCL13 and caused accumulation of B cells with an enhanced B1/B cell ratio in the kidney, worsening of organ damage, and albuminuria. "
12/01/2010 - "Conversely, biglycan deficiency improved systemic and renal outcome in lupus-prone mice, with lower levels of autoantibodies, less enlargement of the spleen and lymph nodes, and reduction in renal damage and albuminuria. "
01/01/2012 - "In the kidney, glomerular lipid accumulation, mesangial expansion, and albuminuria were significantly regressed after treatment with high-dose candesartan, while biglycan and ACAT1 expressions were decreased. "
01/01/2000 - "Glomerular TGF-beta and biglycan-mRNA-expression were determined by Northern blot analysis and albuminuria was measured using a competitive ELISA. "
|2.||Messenger RNA (mRNA)
|4.||Collagen Type I (Type I Collagen)
|1.||Fat-Restricted Diet (Diet, Fat Restricted)
|4.||Homologous Transplantation (Allograft)
|5.||Heterologous Transplantation (Xenotransplantation)